April 07, 2026

FDA Approves First Generic Versions of FARXIGA

Agency approves multiple dapagliflozin generics to reduce heart failure hospitalization risk and improve glycemic control in adults with type 2 diabetes

Conexiant

April 07, 2026

SGLT2 Inhibitors Linked to Lower Epilepsy Risk

Real-world cohort data show lower epilepsy risk vs DPP-4 inhibitors in older patients with type 2 diabetes

Conexiant

April 07, 2026

Maternal Diabetes and the Hidden Risk of ROP

Retrospective cohort study links maternal diabetes to increased ROP risk in premature infants

The Ophthalmologist

April 07, 2026

Hospital-Treated Infections Linked to Dementia Risk

Investigators identify 29 conditions associated with dementia risk in nationwide registry analysis.

Conexiant

April 06, 2026

The Loan Cap That Could Shrink the Doctor Pipeline

New federal limits on medical school borrowing may quietly reshape who becomes a physician—and where they practice.

Conexiant

April 06, 2026

Deprescribing Seen in T2D Care

Researchers examine medication changes in practices with lifestyle medicine access

Conexiant

April 03, 2026

Was the GLP-1 Problem Always Cost?

A JAMA Viewpoint argues the BALANCE model targets the leading cause of discontinuation.

Conexiant

April 02, 2026

Mediterranean Diet Linked to Higher Levels of Mitochondrial Microproteins

Greater adherence was associated with lower oxidative stress markers in older patients.

Conexiant

April 01, 2026

FDA Approves Lilly’s Foundayo Oral GLP-1 Pill

The newly approved therapy offers a noninjectable option that can be taken at any time of day without food or water restrictions.

Conexiant

April 01, 2026

Evolocumab Reduced CV Events in Diabetes

Subgroup analysis of the VESALIUS-CV trial supports earlier intensive lipid lowering

Conexiant